ArticleScientific reports2026
Conformational dynamics and binding free energy analyses unveil a stable flavonoid inhibitor of dengue virus NS5 polymerase.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Computational discovery of DENV-3 RdRp allosteric inhibitors: biological evaluation and mechanistic studies.Molecular diversity · 2026Article
- A bivalent multi-epitope vaccine targeting CSP and TRAP of Plasmodium vivax designed through immunoinformatics and structural bioinformatics.BMC microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The persistent global spread of dengue virus (DENV) necessitates the identification of novel antiviral therapeutics. The RNA-dependent RNA polymerase (RdRp) domain of the non-structural protein 5 (NS5) is a validated target for therapy due to its critical roles in viral genome replication. In this study, we used a structure-guided virtual screening approach to identify potent phytochemical inhibitors of DENV RdRp from the Plant Secondary Compound Database (PSC-db) by focusing on 326 flavonoids. Following drug-likeness filtering and hierarchical docking with MM-GBSA analysis, five top candidates were identified, with PSCdb01560 emerging as the most promising. Subsequent molecular dynamics simulations over 500 ns revealed PSCdb01560's exceptional binding stability, characterised by low protein-ligand RMSD and sustained binding stability. Free energy landscape analysis demonstrated its occupation of deep, well-defined conformational basins. At the same time, post-MD MM-GBSA yielded a binding free energy of -91.65 kcal/mol-outperforming the reference compound. Structural superimposition confirmed strong conformational fidelity between docked and minimum-energy poses (RMSD 1.68 Å). Together, our approach points toward PSCdb01560 as the putative inhibitor molecule that outperforms existing flavonoid leads in thermodynamic and kinetic descriptors. The results thus provide the avenue for experimental validation, such as enzymatic and antiviral screens, in hopes of turning these in silico observations into viable therapeutic development for dengue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.